Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3525 Prognostic factors for progression-free survival (PFS) in patients with metastatic bronchopulmonary neuroendocrine tumors (BP-NETs): Exploratory data from the phase 3 SPINET study

Introduction: SPINET (NCT02683941) evaluated lanreotide autogel/depot (LAN) in metastatic somatostatin receptor (SSTR)-positive typical and atypical (TC and AC) BP NETs.

Conference:

Presenting Author: Baudin E

Authors: Baudin E, Hörsch D, Singh S, Caplin M, Ferone D,

Keywords: bronchopulmonary neuroendocrine tumor, lanreotide autogel/depot, prognostic factor, spinet, typical/atypical carcinoid,

#3518 Effect of lanreotide autogel/depot (LAN) on tumor growth rate (TGR) in patients with metastatic bronchopulmonary neuroendocrine tumors (BP-NETs): Exploratory data from the phase 3 SPINET study

Introduction: SPINET (NCT02683941) evaluated LAN in metastatic somatostatin receptor (SSTR)-positive typical and atypical carcinoid (TC and AC) BP-NETs.

Conference:

Presenting Author: Capdevila J

Authors: Baudin E, Hörsch D, Singh S, Caplin M, Ferone D,

Keywords: bronchopulmonary neuroendocrine tumor, lanreotide autogel/depot, spinet, tumor growth rate, typical/atypical carcinoid,

#3281 Prediction of progression-free survival in patients with neuroendocrine tumors received 177Lu-Dotatate using circulating biomarkers

Introduction: Few circulating biomarkers are available for prediction of progression-free survival (PFS) in patients with advanced neuroendocrine tumors (NET) received 177Lu-Dotatate.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Chen L, Gnanasegaran G, Mandair D, Toumpanakis C, Caplin M,

Keywords: PRRT, survival, ESR, creatinine, CgA,

#3208 Overall outcome of peptide receptor radionuclide therapy (PRRT) in treatment metastatic progressive neuroendocrine tumors (NETs): Survival, toxicity and prognostic factors

Introduction: NETs are a group of malignancies that frequently express somatostatin receptors which allow treatment with PRRT.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Alsadik S, Gnanasegaran G, Chen L, Toumpanakis C, Caplin M,

Keywords: neuroendocrine tumor, NET, peptide receptor radionuclide therapy PRRT,

#3206 Efficacy and safety of peptide receptor radionuclide therapy (PRRT) in patients with chronic kidney disease (CKD)

Introduction: The kidney is a dose-limiting organ in PRRT. Most clinical studies have focused on the safety of PRRT with normal or mildly impaired kidney function.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Alsadik S, Gnanasegaran G, Chen L, Toumpanakis C, Caplin M,

Keywords: neuroendocrine tumor, peptide receptor radionuclide therapy PRRT, 177lu-DOTATATE, chronic kidney disease,